154 related articles for article (PubMed ID: 26805684)
1. Impact of Resecting Radiation Necrosis and Pseudoprogression on Survival of Patients with Glioblastoma.
Grossman R; Shimony N; Hadelsberg U; Soffer D; Sitt R; Strauss N; Corn BW; Ram Z
World Neurosurg; 2016 May; 89():37-41. PubMed ID: 26805684
[TBL] [Abstract][Full Text] [Related]
2. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
[TBL] [Abstract][Full Text] [Related]
3. Defining pseudoprogression in glioblastoma multiforme.
Van Mieghem E; Wozniak A; Geussens Y; Menten J; De Vleeschouwer S; Van Calenbergh F; Sciot R; Van Gool S; Bechter OE; Demaerel P; Wilms G; Clement PM
Eur J Neurol; 2013 Oct; 20(10):1335-41. PubMed ID: 23679051
[TBL] [Abstract][Full Text] [Related]
4. Results of excision of cerebral radionecrosis: experience in patients treated with radiation therapy for nasopharyngeal carcinoma.
Wong ST; Loo KT; Yam KY; Hung WM; Fok KF; Yuen SC; Fong D
J Neurosurg; 2010 Aug; 113(2):293-300. PubMed ID: 20151776
[TBL] [Abstract][Full Text] [Related]
5. Management of Cerebral Radiation Necrosis: A Retrospective Study of 12 Patients.
Liao C; Visocchi M; Zhang W; Yang M; Zhong W; Liu P
Acta Neurochir Suppl; 2017; 124():195-201. PubMed ID: 28120074
[TBL] [Abstract][Full Text] [Related]
6. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
8. Re-do Craniotomy for Recurrent Grade IV Glioblastomas: Impact and Outcomes from the National Neuroscience Institute Singapore.
Chen MW; Morsy AA; Liang S; Ng WH
World Neurosurg; 2016 Mar; 87():439-45. PubMed ID: 26585720
[TBL] [Abstract][Full Text] [Related]
9. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
10. Repeat-surgery at Glioblastoma recurrence, when and why to operate?
Ening G; Huynh MT; Schmieder K; Brenke C
Clin Neurol Neurosurg; 2015 Sep; 136():89-94. PubMed ID: 26092644
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.
Gahramanov S; Varallyay C; Tyson RM; Lacy C; Fu R; Netto JP; Nasseri M; White T; Woltjer RL; Gultekin SH; Neuwelt EA
CNS Oncol; 2014 Nov; 3(6):389-400. PubMed ID: 25438810
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series.
Himes BT; Arnett AL; Merrell KW; Gates MJ; Bhargav AG; Raghunathan A; Brown DA; Burns TC; Parney IF
Can J Neurol Sci; 2020 Jul; 47(4):525-530. PubMed ID: 32077389
[TBL] [Abstract][Full Text] [Related]
15. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful?
Forsyth PA; Kelly PJ; Cascino TL; Scheithauer BW; Shaw EG; Dinapoli RP; Atkinson EJ
J Neurosurg; 1995 Mar; 82(3):436-44. PubMed ID: 7861222
[TBL] [Abstract][Full Text] [Related]
16. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
17. Histopathological correlates with survival in reoperated glioblastomas.
Woodworth GF; Garzon-Muvdi T; Ye X; Blakeley JO; Weingart JD; Burger PC
J Neurooncol; 2013 Jul; 113(3):485-93. PubMed ID: 23666202
[TBL] [Abstract][Full Text] [Related]
18. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.
Clark AJ; Lamborn KR; Butowski NA; Chang SM; Prados MD; Clarke JL; McDermott MW; Parsa AT; Berger MS; Aghi MK
Neurosurgery; 2012 Feb; 70(2):361-70. PubMed ID: 21841523
[TBL] [Abstract][Full Text] [Related]
19. Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?
Patrizz A; Dono A; Zhu P; Tandon N; Ballester LY; Esquenazi Y
J Neurooncol; 2021 Mar; 152(1):163-172. PubMed ID: 33481149
[TBL] [Abstract][Full Text] [Related]
20. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
